Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19070296&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Novel therapeutic modalities in pediatric inflammatory bowel disease Shteyer E; Wilschanski MIsr Med Assoc J 2008[Nov]; 10 (11): 816-20Management of inflammatory bowel disease in childhood poses great challenges. Apart from the disease complications, the drugs' adverse affects, especially corticosteroids, are significant. In the past decade major progress was made in elucidating the pathogenesis of IBD, which led to new treatment options aiming to achieve better control of the disease and decrease the various complications of current therapy. In this review we provide an overview of novel therapies for IBD, their efficacy, safety and their current use in children.|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Basiliximab[MESH]|Child[MESH]|Crohn Disease/*drug therapy/metabolism[MESH]|Enzyme Inhibitors/therapeutic use[MESH]|Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use[MESH]|Humans[MESH]|Immunosuppressive Agents/therapeutic use[MESH]|Inflammatory Bowel Diseases/*drug therapy/metabolism[MESH]|Integrin alpha4[MESH]|Mycophenolic Acid/therapeutic use[MESH]|Natalizumab[MESH]|Probiotics/therapeutic use[MESH]|Receptors, Interleukin-6/antagonists & inhibitors[MESH]|Recombinant Fusion Proteins/therapeutic use[MESH]|Tacrolimus/therapeutic use[MESH]|Treatment Outcome[MESH] |
